Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER vs ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Dextrose is a monosaccharide that provides calories for metabolic processes, restoring blood glucose levels and reducing protein and fat catabolism. Sodium chloride maintains osmolarity and replaces sodium and chloride losses.
Acyclovir is a synthetic purine nucleoside analog with inhibitory activity against herpes simplex virus types 1 (HSV-1) and 2 (HSV-2), and varicella-zoster virus (VZV). After intracellular conversion to acyclovir triphosphate, it inhibits viral DNA polymerase, leading to chain termination and viral DNA replication inhibition.
Parenteral source of carbohydrates and electrolytes,Treatment of fluid and electrolyte depletion,Maintenance fluid therapy,Correction of hypovolemia
Treatment of herpes simplex virus (HSV) infections (genital herpes, herpes labialis, herpes simplex encephalitis),Treatment of varicella-zoster virus (VZV) infections (chickenpox, herpes zoster),Neonatal herpes simplex virus infection,Off-label: Prevention of HSV reactivation in immunocompromised patients, treatment of eczema herpeticum
Intravenous infusion. Adult: 500-1000 m L per dose at a rate of 2-6 m L/min, frequency dependent on fluid and electrolyte needs. Maximum 40 m L/kg/day.
5 mg/kg IV every 8 hours (or 10 mg/kg IV every 8 hours for varicella-zoster or herpes simplex encephalitis) infused over 1 hour.
Glucose half-life is approximately 1.5-2 hours in normal individuals, prolonged in renal impairment or diabetes. Sodium and chloride have no defined half-life as they are electrolytes; their elimination depends on renal function and hydration status.
Terminal elimination half-life in adults with normal renal function is 2.5-3.3 hours. In anuric patients, half-life extends to approximately 19.5 hours, necessitating dosage adjustment in renal impairment.
Dextrose is metabolized via glycolysis and the citric acid cycle; insulin-dependent uptake. Sodium chloride is not metabolized; excreted renally.
Acyclovir is partially metabolized by aldehyde oxidase and alcohol dehydrogenase to 9-carboxymethoxymethylguanine and other minor metabolites. The majority (62-90%) is excreted unchanged in urine via glomerular filtration and tubular secretion.
Renal: >99% of administered glucose is metabolized or excreted; sodium and chloride are excreted renally. In dextrose 5% and sodium chloride 0.2%, glucose undergoes metabolism to CO2 and water; excess is excreted renally. Sodium and chloride are almost entirely excreted renally with >90% reabsorption under normal conditions.
Primarily renal excretion via glomerular filtration and tubular secretion; approximately 62-91% of an administered dose is recovered unchanged in urine. Fecal excretion is minimal (<2%).
Glucose: negligible (<1%). Sodium and chloride: not protein bound.
9-33% bound to plasma proteins; binding is concentration-independent and predominantly to albumin.
Glucose: approximately 0.2-0.25 L/kg; distributes primarily in extracellular fluid. Sodium: 0.6-0.7 L/kg (total body water); chloride: similar. Clinical meaning: initial distribution reflects ECF volume; changes indicate fluid shifts.
Approximately 0.7 L/kg, indicating distribution into total body water. Penetrates well into tissues, including cerebrospinal fluid (CSF concentrations ~50% of plasma).
Intravenous: 100% for all components. Not applicable for oral or other routes as this formulation is for IV use only.
Intravenous administration yields 100% bioavailability. Oral bioavailability is 15-30% (not applicable to IV formulation).
For GFR 30-50 m L/min: close monitoring of electrolytes; GFR <30 m L/min: use with caution, monitor for hypernatremia and fluid overload, reduce infusion rate by 50%.
Cr Cl >50 m L/min: no adjustment; Cr Cl 25-50 m L/min: 5-10 mg/kg every 12 hours; Cr Cl 10-25 m L/min: 5-10 mg/kg every 24 hours; Cr Cl <10 m L/min: 2.5-5 mg/kg every 24 hours; hemodialysis: give dose after dialysis.
No specific adjustment required for Child-Pugh class A or B; use with caution in class C due to risk of fluid overload.
No dose adjustment required for hepatic impairment; acyclovir is minimally metabolized by the liver.
Intravenous infusion. 5-10 m L/kg per dose as needed; rate not to exceed 0.5-1 g/kg/hour of dextrose. For neonates, avoid unless specific indication due to high sodium load.
Neonates (0-3 months): 10 mg/kg IV every 8 hours for HSV; Infants and children (3 months-12 years): 10 mg/kg IV every 8 hours for HSV, 20 mg/kg IV every 8 hours for VZV; maximum dose 500 mg/m² per dose.
Reduce initial infusion rate to 1-2 m L/min due to decreased renal function and higher risk of fluid overload; monitor serum sodium and osmolality closely.
Elderly patients may have reduced renal function; adjust dose based on Cr Cl and monitor for neurotoxicity (e.g., confusion, hallucinations).
Solutions containing dextrose may be contraindicated in patients with known allergies to corn or corn products. Intrathecal administration is contraindicated.
None.
Risk of hyperglycemia and hyperosmolar syndrome, especially in patients with diabetes mellitus,May cause fluid and solute overload leading to dilution of serum electrolytes, overhydration, congested states, or pulmonary edema,Use with caution in patients with heart failure, renal impairment, or severe dehydration,Not for use in patients with intracranial or intraspinal hemorrhage,Air embolism risk if administered via pressurized IV lines
Renal impairment: Dose adjustment required; monitor renal function.,Neurotoxicity: May cause agitation, hallucinations, confusion, seizures (especially in elderly or renally impaired).,Crystalluria: Risk increased with rapid infusion or dehydration; ensure adequate hydration.,Hemolytic uremic syndrome/thrombotic thrombocytopenic purpura (HUS/TTP): Rare but serious, reported in immunocompromised patients.,Pregnancy: Use only if clearly needed (Category B).
Hyperglycemia and hyperosmolar coma,Hypersensitivity to corn or corn products,Intrathecal administration,Severe dehydration with hypernatremia,Addison's disease without adequate corticosteroid therapy
Hypersensitivity to acyclovir, valacyclovir, or any component of the formulation.,Neonates: Use of bacteriostatic water-containing preparations (e.g., benzyl alcohol) is contraindicated.
No specific food interactions. Monitor fluid and electrolyte balance especially if patient is on a low-sodium diet. Dextrose may affect blood glucose; adjust meal timing or insulin accordingly.
No specific food interactions. Adequate fluid intake is recommended to prevent renal toxicity. Avoid concurrent use of nephrotoxic substances (e.g., certain NSAIDs, aminoglycosides) without medical supervision.
Dextrose and sodium chloride are physiologic substances. No teratogenic risk is reported; however, hyperglycemia or electrolyte imbalances in the mother may affect the fetus. Use standard precautions.
FDA Pregnancy Category B. No evidence of teratogenicity in animal studies. Limited human data: no increased risk of major birth defects or miscarriage. Risk cannot be ruled out; use only if clearly needed.
Dextrose and sodium chloride are normal blood constituents; transfer into breast milk is not clinically significant. No M/P ratio available; considered safe during breastfeeding.
Acyclovir excreted in breast milk at low levels; M/P ratio unknown. Typical infant dose ~0.6 mg/kg/day (2-3% of maternal IV dose). No adverse effects reported in breastfeeding infants. Compatible with breastfeeding; caution with high maternal doses.
Total body water increases in pregnancy, potentially expanding distribution volume; however, dosing is based on clinical status. Monitor for fluid overload and electrolyte disturbances. No specific dose adjustment is required for standard maintenance infusions.
Increased renal clearance and volume of distribution in pregnancy may reduce acyclovir exposure. No dose adjustment routinely recommended; however, higher doses or more frequent dosing may be considered for severe infections. Monitor therapeutic response.
This isotonic solution provides 170 kcal/L from dextrose and is used for maintenance hydration and electrolyte replacement. Monitor serum glucose in diabetics; may cause hyperglycemia. Contains 34 m Eq/L sodium and 34 m Eq/L chloride. Avoid in patients with hypernatremia, fluid overload, or significant renal impairment. Use with caution in pediatric and elderly patients due to risk of hyponatremia.
Acyclovir in sodium chloride 0.9% preservative-free is for IV administration only; do not administer IM or SC. Infuse over at least 1 hour to prevent renal tubular damage. Monitor renal function and adjust dose in renal impairment (Cr Cl <50 m L/min). Ensure adequate hydration (e.g., 500 m L IV fluids per gram acyclovir) to reduce risk of crystalluria. In obese patients, use ideal body weight for dosing. Phlebitis at infusion site is common; rotate sites.
This solution provides sugar and salt to help maintain body fluids and energy.,Tell your healthcare provider if you have diabetes, heart failure, kidney disease, or are on a low-salt diet.,Report any swelling, shortness of breath, headache, nausea, or changes in urination.,Do not drink this solution; it is given intravenously.
This medication is given intravenously (into a vein) to treat viral infections.,Drink plenty of fluids before and during treatment to prevent kidney problems.,Report any pain, redness, or swelling at the injection site, or any lower back pain.,Tell your healthcare provider if you have kidney disease or are taking other medications that can affect the kidneys.,This drug does not cure herpes infections but helps reduce symptoms and recurrence.
"Lithium cation may increase the excretion rate of Sodium chloride which could result in a lower serum level and potentially a reduction in efficacy."
"The risk or severity of adverse effects can be increased when Sodium chloride is combined with Tolvaptan."
"Teriflunomide, the active metabolite of leflunomide, inhibits dihydroorotate dehydrogenase (DHODH), a key enzyme in de novo pyrimidine synthesis, exerting immunomodulatory effects. Acyclovir, an antiviral nucleoside analog, may inhibit organic anion transporter 3 (OAT3)-mediated renal tubular secretion of teriflunomide, leading to increased systemic exposure. Elevated teriflunomide concentrations can potentiate hepatotoxicity, myelosuppression, and immunosuppression, increasing the risk of infections and other adverse effects."
"The serum concentration of Acyclovir can be increased when it is combined with Tizanidine."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER vs ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE, answered by our medical review team.
DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER is a Electrolyte that works by Dextrose is a monosaccharide that provides calories for metabolic processes, restoring blood glucose levels and reducing protein and fat catabolism. Sodium chloride maintains osmolarity and replaces sodium and chloride losses.. ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE is a Electrolyte that works by Acyclovir is a synthetic purine nucleoside analog with inhibitory activity against herpes simplex virus types 1 (HSV-1) and 2 (HSV-2), and varicella-zoster virus (VZV). After intracellular conversion to acyclovir triphosphate, it inhibits viral DNA polymerase, leading to chain termination and viral DNA replication inhibition.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER and ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE depend on the specific clinical indication. These are both Electrolyte agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER is: Intravenous infusion. Adult: 500-1000 m L per dose at a rate of 2-6 m L/min, frequency dependent on fluid and electrolyte needs. Maximum 40 m L/kg/day.. The standard adult dose of ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE is: 5 mg/kg IV every 8 hours (or 10 mg/kg IV every 8 hours for varicella-zoster or herpes simplex encephalitis) infused over 1 hour.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
A moderate-severity drug interaction has been identified when combining DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER and ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE. The risk or severity of adverse effects can be increased when Sodium chloride is combined with Tolvaptan. Consult your prescriber before combining these medications.
The maternal-fetal safety profiles differ. DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER is classified as Category A/B. Dextrose and sodium chloride are physiologic substances. No teratogenic risk is reported; however, hyperglycemia or electrolyte imbalances in the mother may affect the fetus. Use s. ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE is classified as Category A/B. FDA Pregnancy Category B. No evidence of teratogenicity in animal studies. Limited human data: no increased risk of major birth defects or miscarriage. Risk cannot be ruled out; us. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.